|
|
Post by peppy on Jan 14, 2016 5:58:38 GMT -5
|
|
|
|
Post by alethea on Jan 14, 2016 11:28:10 GMT -5
Thank you Peppy. You are a veritable font of information.  |
|
|
|
Post by lakers on Jan 14, 2016 17:47:11 GMT -5
Peppy, Are you up for Dir. of Mannkind IR now that Matt became CEO ?  |
|
|
|
Post by lakers on Jan 14, 2016 19:16:23 GMT -5
jpmorgan.metameetings.com/confbook/healthcare16/ciwc.php?webfeed=1&p=19953MannKind Corp. MNKD:US Presenting: Wednesday, January 13th at 03:30 PM Location: California East Q&A Session: 04:00 PM, Yorkshire Room Speakers: Matthew Pfeffer, CEO, CFO, and Corporate VP, Head of Investor Relations • Ray Urbanski, Chief Medical Officer Slides Bios Email This Print Profile MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Companys lead investigational product candidate is the Technosphere Insulin System. Company Details Website: www.mannkindcorp.comShare Data As of 17:20:00 ET on 01/14/2016 · NASDAQ GM Price: 0.91 USD · Volume: 7,975,782 Day's Range: 0.85 - 0.91 Market Cap: 389.653 (m USD) Research Analyst Analyst: Cory Kasimov (biography) 12126225266 cory.w.kasimov@jpmorgan.com
|
|
|
|
Post by mnholdem on Jan 18, 2016 14:10:16 GMT -5
The slide deck used at the 34th Annual J.P. Morgan Healthcare Conference is now available at the MannKind Corporate website.
www.mannkindcorp.com/
See Spotlight on Homepage. |
|
